SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc., announced today that the United States Patent and Trademark Office Board of Patent Appeals and Interferences handed down a decision in the interference between U.S. Patent No. 6,855,510, assigned to Dana-Farber Cancer Institute and licensed to FibroGen (“Kaelin”), and the pending U.S. Patent Application Serial No. 10/472,595, assigned to Isis Innovation Ltd, and sublicensed to Amgen, Inc. (“Maxwell”). The Kaelin patent covers assays for identifying small molecule inhibitors of Hypoxia Inducible Factor (HIF) prolyl hydroxylase and methods for treating HIF-related disorders using HIF technology.
